In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Patients with heart failure benefit from dapagliflozin regardless of ejection fraction

Pooled analysis of DAPA-HF and DELIVER presented in a Hot Line Session today at ESC Congress 2022

Chronic Heart Failure
Cardiovascular Pharmacotherapy

Barcelona, Spain – 27 Aug 2022: Dapagliflozin reduces the risks of death and cardiovascular events in patients with heart failure regardless of ejection fraction, according to late breaking research presented in a Hot Line session today at ESC Congress 2022.1

This pre-specified patient-level meta-analysis combined the DAPA-HF2 and DELIVER3 trials of the SGLT2 inhibitor dapagliflozin in patients with heart failure. DAPA-HF enrolled patients with reduced ejection fraction (40% or less) and DELIVER enrolled patients with mildly reduced and preserved ejection fraction (above 40%). Both trials randomly allocated participants to dapagliflozin 10 mg once daily or placebo.

The first aim of this analysis was to examine the effect of dapagliflozin on a number of secondary outcomes that each trial alone was not powered to examine. The second aim was to examine if dapagliflozin was effective across the entire range of ejection fraction, since the EMPEROR-Preserved trial previously suggested that the effect of empagliflozin, another SGLT2 inhibitor, may be attenuated in patients with higher ejection fraction.4

A total of 11,007 patients were randomised to dapagliflozin or placebo in the two trials. Survival analysis was used to examine the effect of dapagliflozin on death from cardiovascular causes; death from any cause; total hospital admissions for heart failure; and the composite of death from cardiovascular causes, myocardial infarction, or stroke (major adverse cardiovascular events; MACE).

The average age of participants was 69 years and 35% were women. The median follow up was 1.8 years. Dapagliflozin reduced the risk of death from cardiovascular causes by 14% (hazard ratio [HR] 0.86; 95% confidence interval [CI] 0.76–0.97; p=0.01), death from any cause by 10% (HR 0.90; 95% CI 0.82–0.99; p=0.03), total hospital admissions for heart failure by 29% (relative risk [RR] 0.71; 95% CI 0.65–0.78; p<0.001) and MACE by 11% (HR 0.90; 95% CI 0.81–1.00; p=0.045). There was no evidence that the effect of dapagliflozin differed by ejection fraction for any of the outcomes.

Study author Professor Pardeep Jhund of the University of Glasgow, UK said: “Our findings confirm that all patients with heart failure, regardless of ejection fraction, may benefit from dapagliflozin in addition to any other heart failure therapy they are receiving.”



Notes to editor

ESC Press Office
Tel: +33 (0) 7 8531 2036

Follow us on Twitter @ESCardioNews 

The hashtag for ESC Congress 2022 is #ESCCongress.


This press release accompanies both a presentation and an ESC press conference at ESC Congress 2022. It does not necessarily reflect the opinion of the European Society of Cardiology.


Funding: The DELIVER and DAPA-HF trials were funded by AstraZeneca.


Disclosures: PSJ’s employer, the University of Glasgow, has been remunerated by AstraZeneca for working on the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure) and the DELIVER trial (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure). PSJ has received speakers and advisory board fees from AstraZeneca. Speakers and advisory board fees from Novartis, advisory board fees and grants from Boehringer Ingelheim and fees for clinical trial work from Bayer AG and NovoNordisk.


References and notes

1Pooled analysis of DAPA-HF and DELIVER will be discussed during Hot Line Session 4 on Saturday 27 August at 16:30 to 17:30 CEST in the Barcelona auditorium.

2McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2008.

3DELIVER is being presented during Hot Line Session 4 at ESC Congress 2022 by Professor Scott Solomon.

4Butler J, Packer M, Filippatos G, et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J. 2022;43:416–426.


About the European Society of Cardiology

The ESC brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.

About ESC Congress 2022

It is the world’s largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in Barcelona and online – from 26 to 29 August. Explore the scientific programme. More information is available from the ESC Press Office at